Boston Scientific disclosed a cybersecurity incident on August 26, 2026, first detected a day earlier, that has disabled critical IT systems supporting order processing and shipping across its global operations, and filed an SEC Form 8-K. The medical device maker activated its incident-response plan and engaged third-party experts but has not determined the full scope or whether the breach is reasonably likely to have a material impact; no attacker has been identified and there are no confirmed reports of data theft or ransomware demands. The disruption does not directly affect its medical device portfolio, and work continues on key therapies including FARAPULSE and WATCHMAN. Hospitals and surgical centers may face delays on devices including time-sensitive implants, while more than 7,000 employees in Ireland have been told to work from home. Shares dropped roughly 4% to 5.8% in premarket trading and as much as 6% in earlier trading, were down 4.32% at $47.70 at later publication, and subsequently declined to $48.17, down 3.39%. Evercore ISI analysts project a 600 to 700 basis point, or 6% to 7%, hit to third-quarter revenues if recovery follows the roughly three-week pattern of Stryker’s March cyberattack, implying hundreds of millions of dollars in delayed or lost sales against an approximately $20 billion annual revenue run rate. On the same day the company reported revenue of $5.442 billion, above the $5.361 billion consensus and its $5.34 billion–$5.44 billion guidance, while cutting its fiscal 2026 outlook on Watchman and EP market pressures. Boston Scientific, with a market value of about $72 billion, has seen shares nearly halved this year; the episode adds to healthcare and medtech cyberattacks that BlackFog found accounted for 22% of disclosed attacks in 2025.